Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AEON BiopharmaAEON -4.11%23 3-Year EBITDA Growth Rate is 78.20% as of Jun. 2026, which is 50% above its 10-year median of 52.30. GuruFocus rates AEON with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,130 Biotechnology companies, AEON Biopharma ranks better than 96.19% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 78.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of AEON Biopharma was 78.20% per year. The lowest was 26.40% per year. And the median was 52.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
AEON Biopharma 3-Year EBITDA Growth Rate Related Terms
AEON vs XCUR, PBM, KPRX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, AEON Biopharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AEON Biopharma 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AEON Biopharma's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where AEON Biopharma's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 78.20% mean?
AEON Biopharma (AEON) has a 3-Year EBITDA Growth Rate of 78.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for AEON Biopharma and its competitors. This is 50% above median its historical median of 52.30. Over the past decade, AEON Biopharma's 3-Year EBITDA Growth Rate has ranged from 26.40 to 78.20. According to the industry distribution chart, AEON Biopharma ranks #43 out of 1130 companies in the Biotechnology industry, placing it in the top 3.8%.
Is AEON Biopharma's 3-Year EBITDA Growth Rate too high?
AEON Biopharma's current 3-Year EBITDA Growth Rate of 78.20% is 50% above median its 10-year median of 52.30. Over the past 10 years, this metric has ranged from a low of 26.40 to a high of 78.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. AEON Biopharma's value of 78.20% is 426.6% above this industry median. Based on the distribution chart, AEON Biopharma ranks #43 out of 1130 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AEON Biopharma has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does AEON Biopharma's 3-Year EBITDA Growth Rate compare to XCUR and PBM?
According to the Biotechnology industry distribution chart, AEON Biopharma ranks #43 out of 1130 companies for 3-Year EBITDA Growth Rate. This places AEON Biopharma in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. AEON Biopharma's value of 78.20% is 426.6% above this benchmark. Historically, AEON Biopharma's own 3-Year EBITDA Growth Rate has ranged from 26.40 to 78.20 over the past decade. While the company's 10-year median is 52.30 vs. the industry median of 14.85, AEON Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AEON Biopharma's current 3-Year EBITDA Growth Rate of 78.20% is 426.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for AEON Biopharma and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AEON Biopharma's current 3-Year EBITDA Growth Rate is 78.20%, which is 50% above median its own 10-year median of 52.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AEON Biopharma stock overvalued right now?
AEON Biopharma (AEON) has a current 3-Year EBITDA Growth Rate of 78.20%. The current 3-Year EBITDA Growth Rate is 78.20%, which is 50% above median its 10-year median of 52.30 and 426.6% above the Biotechnology industry median of 14.85. AEON Biopharma's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For AEON Biopharma (AEON), the current 3-Year EBITDA Growth Rate is 78.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
23GF Score
Get the complete analysis for AEON
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AEON has been successfully added to your 
